The U.S. Migraine Drugs Market is projected to grow from USD 2.22 Billion in 2025 to USD 4.88 Billion by 2035, while Europe is expected to expand from USD 1.83 Billion to USD 3.89 Billion, driven by increasing adoption of preventive migraine therapies, biologics, and CGRP-targeted treatments.
The U.S. Migraine Drugs Market is projected to grow from USD 2.22 Billion in 2025 to USD 4.88 Billion by 2035, while Europe is expected to expand from USD 1.83 Billion to USD 3.89 Billion, driven by increasing adoption of preventive migraine therapies, biologics, and CGRP-targeted treatments.